Landscapes / Targets
IGF-1R
6 drugs act on IGF-1R, in 14 active trials · Any stage · updated 19 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs6
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Unmodified immunoglobulin |
Approved | Apr 2027Phase 4 trial completes | |||
| How it works | An antibody | ||||
| Next date | Apr 2027 · Phase 4 trial completes | ||||
| Also tested for | Thyroid Eye Disease | ||||
| Open drug page | |||||
Monoclonal antibody |
Amgen · Public AMGN |
Approved | — | ||
| How it works | An antibody | ||||
| Also tested for | Thyroid Eye Disease | ||||
| Open drug page | |||||
— |
Phase 3 | Dec 2026Phase 3 trial completes | |||
| Next date | Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Thyroid Eye Disease (TED), Thyroid Eye Disease, TED and 1 more | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Sling Therapeutics +1 |
Phase 3 | 30 Jun 2028Phase 3 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 30 Jun 2028 · Phase 3 trial completes | ||||
| Also tested for | Graves Orbitopathy, Thyroid Eye Disease and 11 more | ||||
| Open drug page | |||||
— |
Phase 3 | — | |||
| Also tested for | Thyroid Eye Disease, Thyroid Eye Disease (TED) | ||||
| Open drug page | |||||
— |
Phase 2 | Jan 2027Phase 2 trial completes | |||
| Next date | Jan 2027 · Phase 2 trial completes | ||||
| Also tested for | Glioblastoma | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 6 of 6 drugs. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · openFDA updated 19 Nov 2026